Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hologic Inc (NQ: HOLX )

82.33 +1.46 (+1.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hologic Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Hologic's Return On Capital Employed Overview
Pulled from Benzinga Pro data, Hologic (NASDAQ:HOLX) posted Q2 earnings of $455.70 million, an increase from Q1 of 8.71%. Sales dropped to $1.44 billion, a 2.38% decrease between quarters. 
Via Benzinga
Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue
Via Benzinga
Raymond James Maintains Outperform Rating for Hologic: Here's What You Need To Know
Raymond James has decided to maintain its Outperform rating of Hologic (NASDAQ:HOLX) and lower its price target from $84.00 to $83.00. Shares of Hologic are trading down 2.08% over the last 24 hours,... 
Via Benzinga
Hologic Announces Financial Results for Second Quarter of Fiscal 2022
From Hologic, Inc.
Via Business Wire
Expert Ratings for Hologic
Analysts have provided the following ratings for Hologic (NASDAQ:HOLX) within the last quarter: 
Via Benzinga
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy
From Hologic, Inc.
Via Business Wire
Hologic: Q1 Earnings Insights
Hologic (NASDAQ:HOLX) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2022 on Wednesday, April 27, 2022
From Hologic, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2022
Upgrades 
Via Benzinga
7 S&P 500 Stocks That Have Raised Their Guidance in 2022
The number of companies raising guidance in 2022 has been slower than usual. Here are seven S&P 500 stocks that have upped guidance. 
Via InvestorPlace
Digital Breast Tomosynthesis Market Size Estimated to Grow at CAGR 13.2% During 2022-2027
Via AB Newswire
Topics Product Recall
Exposures Legal Product Safety
Digital Breast Tomosynthesis Market Size Estimated to Grow at CAGR 13.2% During 2022-2027
Continue reading "Digital Breast Tomosynthesis Market Size Estimated to Grow at CAGR 13.2% During 2022-2027" 
Via Get News
Topics Product Recall
Exposures Legal Product Safety
Death Cross Looms Over Hologic Investors
If history is any guide, there may be trouble ahead for shares of Hologic (NASDAQ:HOLX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Chronic Disease Increasing Need for Specialty Pharmacy Services
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – February 24, 2022 – The average American’s lifespan may have increased to 78 years old, but chronic diseases are are still... 
Via FinancialNewsMedia
Hologic to Webcast Presentations at Upcoming Investor Conferences
From Hologic, Inc.
Via Business Wire
Complete List: Here Are All The Companies With Super Bowl LVI Commercials
Super Bowl LVI aired Sunday on NBC, a unit of Comcast Corp (NASDAQ: 
Via Benzinga
Analyst Ratings For Hologic
Over the past 3 months, 5 analysts have published their opinion on Hologic (NASDAQ:HOLX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Looking Into Hologic's Return On Capital Employed
According to Benzinga Pro, during Q1, Hologic (NASDAQ:HOLX) earned $499.20 million, a 51.82% increase from the preceding quarter. Hologic also posted a total of $1.47 billion in sales, a 11.69%... 
Via Benzinga
Hologic Q1 FY22 Sales Decline 9% On Lower COVID-19 Assay Sales; Issues Upbeat FY22 Outlook
Hologic Inc (NASDAQ: HOLX) reported  
Via Benzinga
Hologic Announces Financial Results for First Quarter of Fiscal 2022
From Hologic, Inc.
Via Business Wire
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For February 2, 2022
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is likely to report quarterly earnings at $1.57 per share on revenue of $24.59 billion. 
Via Benzinga
Hologic Launches First-Ever National Advertising Campaign Featuring Mary J. Blige
From Hologic, Inc.
Via Business Wire
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Hologic’s Sustainability Leadership Makes Company “A Global Force for Good”
From Hologic, Inc.
Via Business Wire
14 Stocks in the Healthcare Sector
Here are 14 companies in the Healthcare Sector that have investment-grade credit ratings of BBB- or better, cash flow yield of 6% or better, future total return of at least 5%. 
Via Talk Markets
A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5%
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the three major averages recorded losses last week. Investors are awaiting earnings... 
Via Benzinga
5 Stocks To Watch For January 10, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Commercial Metals Company (NYSE: CMC) to report quarterly earnings at $1.21 per share on revenue... 
Via Benzinga
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022
From Hologic, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.